Craig-Hallum raised the firm’s price target on Koru Medical (KRMD) to $6 from $5 and keeps a Buy rating on the shares. Koru Medical’s Q4 pre-release points to another “nice” quarter for the company, and a cash flow positive one, the analyst tells investors in a research note. The firm is focused on continued commercial execution and international expansion to drive above market growth in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD: